Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trial

NEXT STORY
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
PREV STORY
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Genmab ansætter Judith Klimovsky, MD, som Chief Development Officer

Selskabsmeddelelse Judith Klimovsky, MD, ansættes som Executive Vice President og Chief Development Officer (CDO) ...

author_avatar
NASDAQ Market News

Insights on the Virtual Clinical Trials Global Market to 2026 – Featuring IQVIA Holdings, ICON PLC and Dassault Systemes Among Others

author_avatar
NASDAQ Market News

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

author_avatar
NASDAQ Market News